Tuesday, April 03, 2012 AGBL-NOVARTIS CML program aims to improve the molecular techniques used to diagnose and monitor Philadelphia P210 patients treated with Glivec. The program aims at establishing accurate quantification of the P210 translocation to assess the molecular response to the drug and diagnose early relapse and remission of